Erratum

Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small cell lung cancer (SCLC) and poor prognosis

Medical Research Council Lung Cancer Working Party (prepared on behalf of the working party and its collaborators by NM Bleehen, DJ Girling, P Hopwood, G Lallemand, D Machin, RJ Stephens and AJ Bailey)

British Journal of Cancer, 1996; 73: 406-413

In the publication of the above paper, a proof correction on Table IV was overlooked. The corrected table is shown below:

| Adverse reaction                        | Estimated percentage of patients | HR* | 95% CI     |
|-----------------------------------------|----------------------------------|-----|------------|
| Alopecia                                | (90)                             | 1.02| 0.77 – 1.35|
| Anorexia                                | (48)                             | 1.14| 0.75 – 1.76|
| Nausea                                  | (61)                             | 1.43| 0.98 – 2.09|
| Vomiting                                | (51)                             | 1.23| 0.82 – 1.85|
| Dysphagia                               | (38)                             | 1.42| 0.86 – 2.34|
| Sore mouth/mucositis                    | (54)                             | 1.99| 1.30 – 3.05|
| Numbness                                | (38)                             | 1.16| 0.73 – 1.85|
| Haematological WHO grade 2 or worse     | (38)                             | 2.17| 1.27 – 3.70|
| Anaemia                                 | (32)                             | 1.97| 1.11 – 3.52|
| Leucopenia                              | (16)                             | 4.18| 1.65 – 10.58|
| Thrombocytopenia                        | (4)                              | 2.30| 0.46 – 11.45|

*HR > 1.0 indicates an advantage to the EV regimen.